Prion diseases (PrDs) are devastating and fatal conditions characterized by the accumulation of the misfolded prion protein (PrPSc) in the central nervous system (CNS). Definitive diagnosis of PrDs relies on the detection of prions in CNS tissues collected postmortem. The advent of a highly sensitive cell-free amplification technique, named protein misfolding cyclic amplification (PMCA), has revolutionized this field. It has revealed trace amounts of prions in various tissues, including cerebrospinal fluid, urine, blood, and olfactory mucosa of patients with different forms of PrDs. PMCA mirrors in vitro the pathological process of protein misfolding and aggregation, which occurs in vivo but in a significantly accelerated manner. For this reason, this technology is currently used in specialized laboratories to support research and diagnostic activities in human and animal PrDs. This chapter highlights the latest advances and applications of PMCA in the diagnosis of human PrDs.

Cazzaniga, F., Bufano, G., Bellandi, F., Bacınoğlu, M., Moda, F. (2025). Detecting the Undetectable: Exploring the Diagnostic Potential of Protein Misfolding Cyclic Amplification in Human Prion Diseases. In G. Legname, F. Moda (a cura di), Biomarkers and Therapeutical Targets for Prion Diseases (pp. 269-291). Springer [10.1007/978-3-031-97055-9_12].

Detecting the Undetectable: Exploring the Diagnostic Potential of Protein Misfolding Cyclic Amplification in Human Prion Diseases

Bufano, Giuseppe;
2025

Abstract

Prion diseases (PrDs) are devastating and fatal conditions characterized by the accumulation of the misfolded prion protein (PrPSc) in the central nervous system (CNS). Definitive diagnosis of PrDs relies on the detection of prions in CNS tissues collected postmortem. The advent of a highly sensitive cell-free amplification technique, named protein misfolding cyclic amplification (PMCA), has revolutionized this field. It has revealed trace amounts of prions in various tissues, including cerebrospinal fluid, urine, blood, and olfactory mucosa of patients with different forms of PrDs. PMCA mirrors in vitro the pathological process of protein misfolding and aggregation, which occurs in vivo but in a significantly accelerated manner. For this reason, this technology is currently used in specialized laboratories to support research and diagnostic activities in human and animal PrDs. This chapter highlights the latest advances and applications of PMCA in the diagnosis of human PrDs.
Capitolo o saggio
Disease biomarkers; Human prion diseases; Neurodegeneration; Protein misfolding cyclic amplification;
English
Biomarkers and Therapeutical Targets for Prion Diseases
Legname, G; Moda, F
2025
9783031970542
112
Springer
269
291
Cazzaniga, F., Bufano, G., Bellandi, F., Bacınoğlu, M., Moda, F. (2025). Detecting the Undetectable: Exploring the Diagnostic Potential of Protein Misfolding Cyclic Amplification in Human Prion Diseases. In G. Legname, F. Moda (a cura di), Biomarkers and Therapeutical Targets for Prion Diseases (pp. 269-291). Springer [10.1007/978-3-031-97055-9_12].
none
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/571065
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
Social impact